首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Development of a Novel Next-Generation Sequencing (NGS)-Based Assay for Measurable Residual Disease (MRD) in FLT3-ITD AML and Its Potential Clinical Application in Patients Treated with Chemotherapy Plus FLT3 Inhibitors
【24h】

Development of a Novel Next-Generation Sequencing (NGS)-Based Assay for Measurable Residual Disease (MRD) in FLT3-ITD AML and Its Potential Clinical Application in Patients Treated with Chemotherapy Plus FLT3 Inhibitors

机译:在FLT3-ITD AML中的可测量残余疾病(MRD)的新的下一代测序(NGS)的研制为基于FLT3-ITD AML及其在用化疗加上FLT3抑制剂治疗的患者中的潜在临床应用

获取原文
获取原文并翻译 | 示例
           

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号